Table 3.
Treatment outcomes by MDR-TB patient group
| Pooled treatment outcomes* | MDR-TB, susceptible to FQ & INJ (“MDR-TB only”) (N=4763) % (95%CI) |
MDR-TB +INJr (N=1130) % (95%CI) |
MDR-TB +FQr (N=426) % (95%CI) |
XDR-TB (N=405) % (95%CI) |
Total (N=6724) % (95%CI) |
|---|---|---|---|---|---|
| Treatment success | 64% (57, 72) | 56% (45, 66) | 48% (36, 60) | 40% (27, 53) | 62% (54,69) |
| Treatment failure or Relapse | 4% (2, 6) | 12% (9, 15) | 18% (14, 21) | 22% (15, 28) | 7% (4, 9) |
| Died | 8% (5, 11) | 8% (3, 14) | 11% (3, 19) | 15% (8, 23) | 9% (5, 12) |
| Defaulted | 18% (12,24) | 16% (7, 24) | 12% (1,23) | 16% (8, 24) | 17% (11, 22) |
From study level meta-analysis; column percentages do not total to 100%. See Methods and Laserson et al (2005) for treatment outcome definitions.
MDR-TB = resistance to at least isoniazid and rifampicin
XDR-TB = MDR-TB plus resistance to any fluoroquinolone and any second-line injectable drug (amikacin/kanamycin and/or capreomycin)
MDR-TB+FQr = MDR-TB plus resistance to any fluoroquinolone, but susceptible to amikacin/kanamycin and/or capreomycin (at least one second-line injectable drug tested)
MDR-TB+INJr = MDR-TB plus resistance to amikacin/kanamycin and/or capreomycin, but susceptible to fluoroquinolones
MDR-TB, susceptible to FQ & INJ = MDR-TB, but susceptible to fluoroquinolones, amikacin/kanamycin and capreomycin (at least one second-line injectable drug tested)
N: Number of cases
CI = confidence intervals